GRAPHICAL ABSTRACT : Imatinib nanoparticles show a strong peak of Plasmon absorption in ultraviolet-visible zone. A strong interaction exists between the surface of Imatinib nanoparticles and different Bcr-Abl tyrosine-kinase inhibitors (TKI) compounds.Different Bcr-Abl tyrosine-kinase inhibitors (TKI) compounds cause to aggregation of Imatinib nanoparticles linked to DNA/RNA and hence, lead to widening of peak Plasmon of Imatinib nanoparticles surface at 760 (nm) and emerging a new peak at higher wavelengths. In the current project, this optical characteristic of Imatinib nanoparticles is used to time investigate of interaction between different Bcr-Abl tyrosine-kinase inhibitors (TKI) and Imatinib nanoparticles. The results were shown that different Bcr-Abl tyrosine-kinase inhibitors (TKI) compounds with shorter chain length interact faster with Imatinib nanoparticles. Therefore, a simple and fast method for identification of Bcr-Abl tyrosine-kinase inhibitors (TKI) with various chain length using red shift in surficial Plasmon absorption is presented.